Evidence map›Paper›PMID 41023551›Full record

ArticleAnnals of surgical oncology2026

Radiologic and Pathologic Response as Predictors of Survival in Patients with Colorectal Peritoneal Metastases Undergoing Neoadjuvant Chemotherapy Followed by CRS-HIPEC: A Retrospective Study.

Jessica Cyr-Cronier, Florence Lebel-Guay, Lucas Sideris, Mai-Kim Gervais, Jean-François Tremblay, Pierre Dubé, Mikaël Lefebvre-Soucisse

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica Cyr-CronierDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada. jessica.cyr-cronier.med@ssss.gouv.qc.ca.
Florence Lebel-GuayDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada.
Lucas SiderisDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada.
Mai-Kim GervaisDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada.
Jean-François TremblayDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada.
Pierre DubéDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada.
Mikaël Lefebvre-SoucisseDivision of Surgical Oncology, Department of Surgery, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'île de Montréal, Université de Montréal, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeritoneal metastases from colorectal cancer (pmCRC) are associated with poor prognosis. Neoadjuvant chemotherapy followed by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival in these patients. However, few studies have evaluated the influence of radiological and pathological responses on overall survival (OS) and recurrence-free survival (RFS) in this population.

objectiveThe objective of this study was to assess these prognostic markers in patients with pmCRC who received neoadjuvant chemotherapy followed by CRS-HIPEC at our institution.

methodsA total of 121 patients with pmCRC treated with neoadjuvant chemotherapy followed by CRS-HIPEC from 2012 to 2023 were included. Demographic, clinical, and oncological data were extracted from medical records. OS and RFS were obtained using Kaplan-Meier analysis. Univariate and multivariate Cox regression analyses were done.

resultsAfter a median follow-up of 44.6 months, median OS was 47.1 months (95% confidence interval [CI] 32.4-61.6) and RFS was 21.8 months (95% CI 13.7-29.9). No significant difference in OS was observed among patients who achieved a partial response on imaging compared with non-responders (hazard ratio [HR] 0.9; 95% CI 0.5-1.5; p = 0.725). Patients who did not achieve a complete pathological response showed a significant difference in OS, with worse OS (HR 3.4; 95% CI 1.3-8.9; p = 0.012). OS was significantly lower in patients with a peritoneal carcinomatosis index >15 (HR 4.1; 95% CI 1.1-15; p = 0.033).

conclusionsRadiological response after neoadjuvant chemotherapy does not significantly affect the OS or RFS of patients with pmCRC. Complete pathological response is a significant prognostic marker for both OS and RFS.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyNeoadjuvant TherapyPeritoneal NeoplasmsAdultAgedChemotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisChemotherapy responseColorectal cancerCRS-HIPECPathological responsePeritoneal carcinomatosisRadiologic response

Identifiers

PMID41023551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.